FDA’s hydroxychloroquine test
Editor’s Commentary: FDA’s decision about the hydroxychloroquine EUA is a test of its independence and credibility
COVID-19 is testing FDA’s leadership. The agency’s performance will affect both the health of COVID-19 patients as well as public trust in the agency.
One of many challenges facing FDA is whether to keep in place or rescind an Emergency Use Authorization (EUA) for chloroquine and hydroxychloroquine -- and how to explain its decision.
An honest explanation is essential because the public needs to know that FDA is prioritizing its interests, that it is making decisions based on science, and that it has resisted the political pressure that appears from the outside to be influencing its decisions.